

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (NO-54) VONAPRUMENT

PRONUNCIATION voe na' proo ment

THERAPEUTIC CLAIM Prevention of vision loss in patients with dry advanced molecular degeneration

CHEMICAL NAMES

Immunoglobulin IgG1 Fab fragment, anti-(human complement C1q) (human-Mus musculus monoclonal ANX007 γ 1-chain), disulfide with human-Mus musculus monoclonal ANX007 κ -chain (ACI)

Immunoglobulin Fab-G1kappa (VH-CH1_L-kappa), anti-[*Homo sapiens* C1q], humanized monoclonal antibody fragment; Fab-G1 VH-CH1 chain (1-229) [VH Musmus/Homsap (*Mus musculus* IGHV1-64*01 (82.5%) -(IGHD)-IGHJ4*01 (92.9%) S123>T (116)/*Homo sapiens* IGHV1-46*01 (79.4%) -(IGHD)-IGHJ6*01 (92.9%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -*Homo sapiens* IGHG1*01 CH1-h (100%), G1m17 CH1 K120 (CH1 K120 (218) (122-219), hinge 1-10 (220-229)) (122-229)], (224-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-9*03 (80.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3, A45.1 (153), V101 (191) (108'-214')], produced in Chinese hamster ovary (CHO) cells, cell line CHO, non-glycosylated

STRUCTURAL FORMULA

Heavy Chain: anti-C1q IgG1-kappa Fab fragment (H):

QVQLVQSGAE	LKKPGASVKV	SCKSSGYHFT	SYWMHWVKQA	PGQGLEWIGV	50
IHPNSGSI	NEKFESRVTI	TVDKSTSTAY	MELSSLRSED	TAVYYCAGER	100
DSTEVLPMDY	WGQGTTVTVS	SASTKGPSVF	PLAPSSKSTS	GGTAALGCLV	150
KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	TVPSSSLGTQ	200
TYICNVNHKP	SNTKVDKKE	PKSCDKTHT			229

Light chain: anti-C1q κ chain (L):

DVQITQSPSS	LSASLGERAT	INCRASKSIN	KYLAWYQQKP	GKAPKLLIYS	50'
GSTLQSGIPA	RFSGSGSGTD	FRTLTISSELP	EDFAMYYCQQ	HNEYPLT	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges: in red, bold text, shaded text indicates interchain (total 5 bridges)

Intra-H (C23-C104)	22-96	148-204
Intra-L (C23-C104)	23'-88'	134'-194'
Inter H-L (h 5-CL 126)	224-214'	

N-terminal glutaminyl cyclization: in purple bold text

1

H VH Q1: Q > pyroglutamyl (pE, 5-oxo-L-prolyl)

CDR-IMGT Regions: **in bold light blue** (protein sequence numbering from above sequence, not IMGT respective sequence numbering)

heavy chain-Fab CDR1-3 (H):	26-33 (8)	51-58 (8)	97-110 (14)
light chain CDR1-3 (L):	27'-32' (6)	50'-52' (3)	89'-97' (9)

MOLECULAR FORMULA C₂₁₁₆H₃₂₈₄N₅₆₂O₆₈₁S₁₄ (non-glycosylated)

MOLECULAR WEIGHT 47.942 kDa

TRADEMARK None as yet

SPONSOR Annexon Biosciences

CODE DESIGNATIONS ANX007

CAS REGISTRY NUMBER 3050549-24-8

UNII 9HLL22LOX6

WHO NUMBER 13987

gbk